# Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

> **NCT06972628** · PHASE2 · RECRUITING · sponsor: **Ebrahim S Delpassand** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer
- Prostate Cancer Patients With Bone Metastasis
- Prostate Cancer (CRPC)
- Prostate Cancer
- Prostate Cancer Metastatic

## Interventions

- **DRUG:** Administering Lutetium-177-PSMA-617 (PLUVICTO)

## Key facts

- **NCT ID:** NCT06972628
- **Lead sponsor:** Ebrahim S Delpassand
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-23
- **Primary completion:** 2027-04-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06972628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06972628, "Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06972628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*